AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) published a new CEO Corner segment on December 10, 2025. CEO Thomas Equels discusses the unmet need in pancreatic cancer and the company’s lead therapy Ampligen (rintatolimod).

The segment summarizes Ampligen’s ongoing clinical evaluation in the DURIPANC Phase 1b/2 trial where it is being tested in combination with AstraZeneca’s Imfinzi (durvalumab). The CEO Corner video and comments are now available on the company website.

Key Figures

Shelf capacity $100 million Form S-3/A shelf registration filed Jun 27, 2025

Cash & investments $2.4M Quarterly cash and investments in Q3 2025 results

Net loss $3.3M Net loss reported in Q3 2025 earnings

Monthly cash burn $550K Expected average monthly burn from Q3 2025 disclosure

S-1 gross proceeds $10 million Planned gross proceeds from up to 1,052,631 Units in S-1/A

Stockholders’ deficit $-3.9M Deficit as of Mar 31, 2025 in NYSE compliance 8-K

Reverse split 1-for-100 Reverse split executed on Jun 12, 2025 per S-1/A

Objective response rate 50% Phase 2 recurrent ovarian cancer trial with Ampligen combination

Market Reality Check

$1.37 Last Close

Volume Volume 92,751 vs 20-day average 61,311; relative volume at 1.51. high

Technical Price 1.49 trading below 200-day MA of 2.40 and far under 52-week high 20.35.

Peers on Argus

Peers show mixed moves: TNFA -9.72%, PMCB -4.31%, HCWB -2.54%, BCLI -0.21%, while NCNA is up 1.90%, suggesting stock-specific factors around AIM rather than a unified biotech move.

Common Catalyst Only one peer (NCNA) has same-day clinical data news, indicating no broad shared catalyst.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Investor presentation	Positive	+2.0%	CEO fireside chat on Ampligen clinical and regulatory strategy.
Nov 18	Earnings update	Negative	-7.6%	Q3 2025 results showing low cash, losses and continued cash burn.
Nov 10	Clinical data update	Positive	-6.4%	Phase 2 ovarian cancer trial detailed with 50% ORR versus lower historical ORRs.
Nov 04	Conference abstract	Positive	-20.4%	Late‑breaking SITC abstract acceptance for Ampligen ovarian cancer study.
Nov 03	Patent grant	Positive	-4.3%	European patent granted for Ampligen use in treating Long COVID fatigue.

Pattern Detected

Recent AIM news has often been positive on clinical or strategic fronts but followed by negative price reactions, indicating a pattern of good news being sold.

Recent Company History

Over the last six weeks, AIM has highlighted multiple developments around Ampligen, including DURIPANC trial updates, ovarian cancer data at the 40th SITC Meeting, and a European patent for Long COVID. An earnings release on Nov 18, 2025 detailed limited cash of $2.4M and ongoing losses. Despite several clinically positive or strategic announcements, the stock frequently declined afterward, framing today’s CEO Corner communication within a backdrop of execution progress but persistent market skepticism.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-06-27

$100 million registered capacity

An effective Form S-3/A shelf dated Jun 27, 2025 authorizes AIM to issue up to $100 million of various securities, providing flexibility to raise capital in tranches but also implying potential future dilution, as illustrated by at least one 424B5 usage.

Market Pulse Summary

This announcement highlights AIM’s continued emphasis on Ampligen’s role in pancreatic cancer via the DURIPANC Phase 1b/2 trial, framed through a CEO Corner segment. In context, recent disclosures showed limited cash of $2.4M, a quarterly net loss of $3.3M, and an effective $100 million shelf, along with past dilution actions such as a 1-for-100 reverse split. Investors may watch for concrete DURIPANC data, balance-sheet strengthening, and any additional use of the shelf as key future signals.

Key Terms

pancreatic cancer medical

"discusses the unmet need in pancreatic cancer and the Company’s lead program"

Pancreatic cancer is a disease in which cells in the pancreas grow out of control, forming a tumor that disrupts the organ’s role in digestion and blood-sugar regulation; because it often spreads early and is hard to detect, outcomes tend to be poor. For investors, it matters because diagnosis rates, treatment advances, drug approvals, and clinical trial results can strongly affect the value of biotech and healthcare companies—think of a breakthrough therapy as a new part that could fix a failing engine and reshape market expectations.

phase 1b/2 medical

"its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination"

Phase 1b/2 is a combined early-stage human study that first checks a drug’s safety and side effects in a small group and then expands to test whether it shows signs of working in patients. Think of it as a product test that first confirms it’s safe to use, then looks for early evidence of benefit; positive results can significantly reduce clinical risk and increase a company’s value, while negative results raise the opposite.

clinical trial medical

"DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca’s Imfinzi"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

AI-generated analysis. Not financial advice.

Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer

OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website.

In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen^® (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca’s Imfinzi^® (durvalumab).

The CEO Corner segment is now available here.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

What did AIM (AIM) announce on December 10, 2025 regarding Ampligen and pancreatic cancer?

AIM published a CEO Corner where CEO Thomas Equels discussed the unmet need in pancreatic cancer and Ampligen’s role in the DURIPANC Phase 1b/2 trial.

What is the DURIPANC trial mentioned by AIM (AIM) in the CEO Corner?

The DURIPANC trial is a Phase 1b/2 clinical study testing Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab).

Where can investors watch AIM (AIM) CEO Thomas Equels’ December 10, 2025 CEO Corner segment?

The CEO Corner segment is available on AIM ImmunoTech’s website via the company’s investor relations/press section.

Does the CEO Corner announce new clinical data or trial results for AIM (AIM)?

The segment discusses the ongoing evaluation of Ampligen in DURIPANC but does not present new, specific clinical readout data in the announcement.

Which partnered therapy is Ampligen being combined with in AIM’s (AIM) DURIPANC trial?

Ampligen is being evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) in the DURIPANC Phase 1b/2 trial.